(19)
(11) EP 2 044 197 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.03.2018 Bulletin 2018/10

(45) Mention of the grant of the patent:
22.11.2017 Bulletin 2017/47

(21) Application number: 07784668.1

(22) Date of filing: 23.07.2007
(51) International Patent Classification (IPC): 
C12N 5/0787(2010.01)
A61P 37/00(2006.01)
A61K 35/14(2015.01)
(86) International application number:
PCT/AU2007/001019
(87) International publication number:
WO 2008/011664 (31.01.2008 Gazette 2008/05)

(54)

METHOD OF PRODUCING A POPULATION OF CELLS

VERFAHREN ZUR HERSTELLUNG EINER ZELLPOPULATION

PROCÉDÉ DE PRODUCTION D'UNE POPULATION DE CELLULES


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 24.07.2006 US 832854 P

(43) Date of publication of application:
08.04.2009 Bulletin 2009/15

(73) Proprietor: The University Of Queensland
St. Lucia, QLD 4072 (AU)

(72) Inventors:
  • NIELSEN, Lars Keld
    St. Lucia, Queensland 4067 (AU)
  • PALFREYMAN, Emma Louise
    Fig Tree Pocket, Queensland 4069 (AU)
  • TIMMINS, Nicholas Eion
    St Lucia, QLD 4067 (AU)

(74) Representative: Müller Fottner Steinecke 
Rechtsanwalts- und Patentanwaltspartnerschaft mbB Römerstraße 16 b
52428 Jülich
52428 Jülich (DE)


(56) References cited: : 
WO-A-98/39413
US-A- 6 146 623
US-B1- 6 835 809
WO-A2-03/080806
US-B1- 6 190 913
   
  • CWIRLA S E ET AL: "Peptide agonist of the thrombopoietin receptor as potent of the natural cytokine", SCIENCE, vol. 276, 13 June 1997 (1997-06-13), pages 1696-1699, XP002941683, ISSN: 0036-8075
  • HEVEHAN D.L. ET AL.: 'Physiologically significant effects of pH and oxygen tension on granulopoiesis' EXPERIMENTAL HEMATOLOGY vol. 28, no. 3, March 2000, pages 267 - 275, XP008101658
  • MILES PRINCE H ET AL: "Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 126, no. 4, August 2004 (2004-08), pages 536-545, ISSN: 0007-1048
  • MAKINO S ET AL: "Ex vivo culture of peripheral blood CD34+ cells: effects of hematopoietic growth factors on production of neutrophilic precursors.", JOURNAL OF HEMATOTHERAPY, vol. 6, no. 5, October 1997 (1997-10), pages 475-489, ISSN: 1061-6128
  • SAWAI N ET AL: "Neutrophilic cell production by combination of stem cell factor and thrombopoietin from CD34(+) cord blood cells in long-term serum-deprived liquid culture.", BLOOD, vol. 93, no. 2, 15 January 1999 (1999-01-15), pages 509-518, ISSN: 0006-4971
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).